John Townsend - 28 Jul 2025 Form 4 Insider Report for Unicycive Therapeutics, Inc. (UNCY)

Reporting relationship: Chief Financial Officer
Issuer ticker: UNCY
Reported as of: 28 Jul 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jul 2025, 16:30:09 UTC
Prior SEC filing: 14 Aug 2024
Next SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ John Townsend

Key filing fact

John Townsend filed Form 4 for Unicycive Therapeutics, Inc. (UNCY) on 30 Jul 2025.

Key facts

This page summarizes John Townsend's Form 4 filing for Unicycive Therapeutics, Inc. (UNCY).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Jul 2025, 16:30.

Change

Previous filing in this sequence was filed on 14 Aug 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001511906 Primary reporting owner

Townsend John

Relationship: Chief Financial Officer
Address: C/O UNICYCIVE THERAPEUTICS, LOS ALTOS
Signature: /s/ John Townsend
Signature date: 30 Jul 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

UNCY transaction Derivative

Stock Options

Award

Transaction value: $0
Shares: +10,000
Change %: +11%
Price: $0.000000
Shares after: 101,557
Date: 28 Jul 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 10,000
Exercise price: $4.71
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

2,500 of the stock options vest on July 28, 2026 and 1/36th of the remaining options vest at the end of each successive month thereafter.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .